搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
1 天
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...
3 天
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...
2 天
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
2 天
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
2 天
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
2 天
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug ...
2 天
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
2 天
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
2 天
on MSN
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in ...
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
1 天
on MSN
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...
FiercePharma
2 天
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med ...
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
2 天
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈